This program of Medications Development for Drugs of Abuse will seek to train future scientists in the field of drug discovery at both the predoctoral and post-doctoral levels with a particular emphasis on therapies related to Drugs of Abuse. It will utilize a multidisciplinary approach including the discovery, design, synthesis and testing of novel therapeutic drugs. The program will encompass modern approaches currently utilized in drug discovery including rational drug design and high throughput screening (HTS). These will be combined with modern synthetic methods used in the preparation of novel drug candidates and combinatorial approaches for the development of suitable compound libraries. In addition, the trainees will be educated in a wide spectrum of drug abuse research a process which will familiarize them with the chemical, biochemical, physiological, pharmacological, and clinical aspects associated with this field of research. The post-doctoral research training component will seek to develop scientists with a strong background in the discovery and synthesis of novel medications for drug abuse treatment. Rational drug design will be combined with high throughput and combinatorial approaches currently utilized in the pharmaceutical industry. Through this program the post-doctoral trainees who may have obtained their earlier education in any of the chemical, pharmaceutical, or biomedical sciences will have an excellent opportunity to develop careers in the medicinal chemistry or molecular pharmacology of drugs of abuse. Predoctoral students will have a choice of three different Ph.D. programs pharmaceutical sciences (medicinal chemistry/drug design); biomedical sciences (molecular pharmacology/drug discovery); chemistry (organic chemistry/drug synthesis). As a result of this program, all of the predoctoral students will receive extensive education in the chemistry and biology of drugs of abuse and will be encouraged to pursue research careers or further training in this field of science. This program which will function within the Center for Drug Discovery is, to our knowledge, a unique approach to develop promising new scientists who will engage in the development of medications to combat drug abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
3T32DA007312-05S3
Application #
7248407
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Shih, Ming L
Project Start
1999-07-01
Project End
2007-06-30
Budget Start
2004-07-01
Budget End
2007-06-30
Support Year
5
Fiscal Year
2006
Total Cost
$336,069
Indirect Cost
Name
Northeastern University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Finnegan, David F; Shelnut, Erin L; Nikas, Spyros P et al. (2015) Novel tail and head group prostamide probes. Bioorg Med Chem Lett 25:1228-31
Shelnut, Erin L; Nikas, Spyros P; Finnegan, David F et al. (2015) Design and synthesis of novel prostaglandin E2 ethanolamide and glycerol ester probes for the putative prostamide receptor(s). Tetrahedron Lett 56:1411-1415
Zhuang, Jianqin; Yang, De-Ping; Nikas, Spyros P et al. (2013) The interaction of fatty acid amide hydrolase (FAAH) inhibitors with an anandamide carrier protein using (19)F-NMR. AAPS J 15:477-82
Li, H; Wood, J T; Whitten, K M et al. (2013) Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells. Br J Pharmacol 170:489-505
Wood, Jodianne T; Smith, Dustin M; Janero, David R et al. (2013) Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sci 92:482-91
Zhuang, Jianqin; Yang, De-Ping; Tian, Xiaoyu et al. (2013) Targeting the Endocannabinoid System for Neuroprotection: A (19)F-NMR Study of a Selective FAAH Inhibitor Binding with an Anandamide Carrier Protein, HSA. J Pharm Pharmacol (Los Angel) 1:
Johnston, Meghan; Bhatt, Shachi R; Sikka, Surina et al. (2012) Assay and inhibition of diacylglycerol lipase activity. Bioorg Med Chem Lett 22:4585-92
West, Jay M; Zvonok, Nikolai; Whitten, Kyle M et al. (2012) Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase. J Proteome Res 11:972-81
West, Jay M; Zvonok, Nikolai; Whitten, Kyle M et al. (2012) Biochemical and mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase inhibition. PLoS One 7:e43877
Duclos Jr, Richard I; Johnston, Meghan; Vadivel, Subramanian K et al. (2011) A methodology for radiolabeling of the endocannabinoid 2-arachidonoylglycerol (2-AG). J Org Chem 76:2049-55

Showing the most recent 10 out of 21 publications